Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (224)	9/28/2001 4:08:26 AM
From: nigel bates	Read Replies (1) \| Respond to of 1022

I don't expect the patents apply to human cell expression, though... Message 16425790 ``Crucell's PER.C6(TM) cell line has been widely accepted by the pharmaceutical industry for the production of vaccines and vector development purposes,'' said Dinko Valerio, CEO of Crucell. ``Our recent research suggests the enormous potential and versatility of PER.C6(TM) for the production of human antibodies and therapeutic proteins. We are convinced that PER.C6 will encounter the same success as the product currently experiences for vaccine production purposes and vector development applications.'